Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CDXS
stocks logo

CDXS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
35.83M
+66.98%
-0.035
-73.08%
14.39M
+90.8%
-0.110
-56%
16.30M
+6.35%
-0.100
-37.5%
Estimates Revision
The market is revising Upward the revenue expectations for Codexis, Inc. (CDXS) for FY2025, with the revenue forecasts being adjusted by 0.98% over the past three months. During the same period, the stock price has changed by -24.79%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.98%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.55%
In Past 3 Month
Stock Price
Go Down
down Image
-24.79%
In Past 3 Month
Wall Street analysts forecast CDXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDXS is 6.00 USD with a low forecast of 2.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CDXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDXS is 6.00 USD with a low forecast of 2.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.820
sliders
Low
2.00
Averages
6.00
High
11.00
Current: 1.820
sliders
Low
2.00
Averages
6.00
High
11.00
no data image
No Data

Valuation Metrics

The current forward P/E ratio for Codexis Inc (CDXS.O) is -5.45, compared to its 5-year average forward P/E of -23.39. For a more detailed relative valuation and DCF analysis to assess Codexis Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-23.39
Current PE
-5.45
Overvalued PE
5.80
Undervalued PE
-52.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-17.03
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.97
Undervalued EV/EBITDA
-38.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.58
Current PS
0.00
Overvalued PS
11.57
Undervalued PS
1.59
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CDXS News & Events

Events Timeline

(ET)
2025-11-10
09:07:11
Codexis Reveals Lease Agreement for GMP Manufacturing Facility
select
2025-11-06 (ET)
2025-11-06
17:32:22
Codexis Announces Q3 Earnings Per Share of 22 Cents, Exceeding Consensus Estimate of 13 Cents
select
2025-10-29 (ET)
2025-10-29
10:04:23
Codexis and Nitto Denko Avecia Sign Evaluation Agreement
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-05NASDAQ.COM
Tarsus Pharmaceuticals, Inc. (TARS) Posts Q3 Loss but Exceeds Revenue Projections

  • Quarterly Performance: Tarsus Pharmaceuticals reported a quarterly loss of $0.30 per share, better than the expected loss of $0.35, and significantly improved from a loss of $0.61 per share a year ago, marking a 14.29% earnings surprise.

  • Revenue Growth: The company achieved revenues of $118.7 million for the quarter, exceeding the Zacks Consensus Estimate by 2.80% and showing substantial growth from $48.12 million in the same quarter last year.

  • Stock Outlook: Tarsus Pharmaceuticals has seen a 26% increase in its stock price since the beginning of the year, outperforming the S&P 500, but the future performance will depend on management's commentary and earnings estimate revisions.

  • Industry Context: The Medical - Biomedical and Genetics industry, where Tarsus operates, ranks in the top 39% of Zacks industries, indicating a favorable outlook, while Codexis, another company in the same sector, is set to report its quarterly results soon.

[object Object]
Preview
7.5
10-29PRnewswire
Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing

  • Collaboration Announcement: Codexis, Inc. and Nitto Denko Avecia, Inc. have entered into an evaluation agreement to assess Codexis' ECO Synthesis® Manufacturing Platform for oligonucleotide therapeutics.

  • Innovative Manufacturing Approach: The ECO Synthesis platform aims to replace traditional solid-phase oligonucleotide synthesis with a more flexible, enzyme-catalyzed method designed for scalability and sustainability in therapeutic development.

  • Leadership Statements: Both companies' executives expressed enthusiasm for the partnership, highlighting its potential to advance the manufacturing of high-quality therapeutics and redefine industry standards.

  • Company Backgrounds: Codexis is known for its enzymatic solutions in therapeutic manufacturing, while Nitto Denko Avecia specializes in oligonucleotide therapeutics, boasting extensive experience and a comprehensive service portfolio.

[object Object]
Preview
9.5
10-23Newsfilter
Codexis Scheduled to Release Q3 2025 Financial Results on November 6

  • Financial Results Announcement: Codexis, Inc. will report its third-quarter financial results on November 6, 2025, after market close, followed by a conference call at 4:30 pm ET for discussion and updates.

  • Accessing the Call: Participants can join the live webcast on the Codexis Investor Relations website, with a replay available for 48 hours via specific phone numbers.

  • Company Overview: Codexis specializes in enzymatic solutions for manufacturing complex therapeutics, utilizing its CodeEvolver® technology to enhance enzyme performance and efficiency.

  • Innovative Manufacturing Platform: The company is developing the ECO Synthesis™ platform to facilitate the scalable production of RNAi therapeutics through enzymatic methods, aiming for higher yields and reduced environmental impact.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Codexis Inc (CDXS) stock price today?

The current price of CDXS is 1.82 USD — it has increased 2.82 % in the last trading day.

arrow icon

What is Codexis Inc (CDXS)'s business?

Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

arrow icon

What is the price predicton of CDXS Stock?

Wall Street analysts forecast CDXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDXS is 6.00 USD with a low forecast of 2.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Codexis Inc (CDXS)'s revenue for the last quarter?

Codexis Inc revenue for the last quarter amounts to 8.60M USD, decreased -32.98 % YoY.

arrow icon

What is Codexis Inc (CDXS)'s earnings per share (EPS) for the last quarter?

Codexis Inc. EPS for the last quarter amounts to -0.22 USD, decreased -24.14 % YoY.

arrow icon

What changes have occurred in the market's expectations for Codexis Inc (CDXS)'s fundamentals?

The market is revising Upward the revenue expectations for Codexis, Inc. (CDXS) for FY2025, with the revenue forecasts being adjusted by 0.98% over the past three months. During the same period, the stock price has changed by -24.79%.
arrow icon

How many employees does Codexis Inc (CDXS). have?

Codexis Inc (CDXS) has 188 emplpoyees as of December 05 2025.

arrow icon

What is Codexis Inc (CDXS) market cap?

Today CDXS has the market capitalization of 152.20M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free